Access

Letter

Nature Genetics 41, 1105–1109 (1 October 2009) | doi:10.1038/ng.449

Genome-wide association of IL28B with response to pegylated interferon-|[alpha]| and ribavirin therapy for chronic hepatitis C

Yasuhito Tanaka , Nao Nishida , Masaya Sugiyama , Masayuki Kurosaki , Kentaro Matsuura , Naoya Sakamoto , Mina Nakagawa , Masaaki Korenaga , Keisuke Hino , Shuhei Hige , Yoshito Ito , Eiji Mita , Eiji Tanaka , Satoshi Mochida , Yoshikazu Murawaki , Masao Honda , Akito Sakai , Yoichi Hiasa , Shuhei Nishiguchi , Asako Koike , Isao Sakaida , Masatoshi Imamura , Kiyoaki Ito , Koji Yano , Naohiko Masaki , Fuminaka Sugauchi , Namiki Izumi , Katsushi Tokunaga & Masashi Mizokami

The recommended treatment for patients with chronic hepatitis C, pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients. We report a genome-wide association study (GWAS) to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population.